A detailed history of Vanguard Group Inc transactions in Pmv Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,452,111 shares of PMVP stock, worth $4.12 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,452,111
Previous 2,405,307 1.95%
Holding current value
$4.12 Million
Previous $7.46 Million 44.1%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$1.51 - $3.12 $70,674 - $146,028
46,804 Added 1.95%
2,452,111 $4.17 Million
Q4 2023

Feb 14, 2024

BUY
$1.23 - $6.6 $446,472 - $2.4 Million
362,986 Added 17.77%
2,405,307 $7.46 Million
Q3 2023

Nov 14, 2023

BUY
$6.01 - $8.93 $43,800 - $65,081
7,288 Added 0.36%
2,042,321 $12.5 Million
Q2 2023

Aug 14, 2023

BUY
$3.94 - $6.27 $282,155 - $449,013
71,613 Added 3.65%
2,035,033 $12.7 Million
Q1 2023

May 15, 2023

SELL
$4.77 - $9.16 $3.77 Million - $7.24 Million
-790,186 Reduced 28.7%
1,963,420 $9.37 Million
Q4 2022

Feb 10, 2023

SELL
$8.17 - $12.95 $5.56 Million - $8.81 Million
-680,359 Reduced 19.81%
2,753,606 $24 Million
Q3 2022

Nov 14, 2022

BUY
$11.4 - $17.18 $889,211 - $1.34 Million
78,001 Added 2.32%
3,433,965 $40.9 Million
Q2 2022

Aug 12, 2022

BUY
$9.23 - $22.43 $5.7 Million - $13.8 Million
617,081 Added 22.53%
3,355,964 $47.8 Million
Q1 2022

May 13, 2022

BUY
$14.86 - $23.55 $1.35 Million - $2.14 Million
90,937 Added 3.43%
2,738,883 $57 Million
Q4 2021

Feb 14, 2022

SELL
$19.99 - $30.24 $108,905 - $164,747
-5,448 Reduced 0.21%
2,647,946 $61.2 Million
Q3 2021

Nov 12, 2021

BUY
$26.84 - $36.58 $11 Million - $15.1 Million
411,683 Added 18.36%
2,653,394 $79.1 Million
Q2 2021

Aug 13, 2021

BUY
$28.01 - $36.01 $62.8 Million - $80.7 Million
2,241,711 New
2,241,711 $76.6 Million

Others Institutions Holding PMVP

About PMV Pharmaceuticals, Inc.


  • Ticker PMVP
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,622,600
  • Market Cap $76.6M
  • Description
  • PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also d...
More about PMVP
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.